CT-Guided Cryoablation Shows 5-Year Kidney Cancer Control
Research presented at IKCS: North America 2026 in Dallas reports durable disease control for small renal tumors treated with cryoablation.
Updated on Nov. 20, 2026 in Cancer

Research presented at IKCS: North America 2026 reported that CT-guided percutaneous cryoablation provided durable five-year disease control in patients with cT1a renal cell carcinoma. The study drew on 757 patients in the European Registry for Renal Cryoablation (EuRECA).
Why it matters
The findings add long-term outcome data for a minimally invasive option in patients who are less suitable for surgery. Five-year survival and recurrence figures help clinicians weigh cryoablation against other treatments for small kidney tumors.
The registry reported 5-year local recurrence-free survival of 96.1% and overall survival of 86.1% across 757 patients with a 5.0-year median follow-up. The study did not report a direct comparison against surgical outcomes in the same patient group.
The players
European Registry for Renal Cryoablation (EuRECA)
A multicenter European registry that collects outcome data on patients treated with renal cryoablation.
IKCS: North America 2026
A North American kidney cancer scientific conference at which the research was presented in Dallas, Texas.
The details
Researchers reviewed patients treated with CT-guided percutaneous cryoablation for biopsy-proven cT1a renal cell carcinoma between 2014 and 2020. Primary technique efficacy was achieved in 741 patients (97.9%), while 28 developed local recurrence and four died from the disease; repeat cryoablation achieved 87.5% efficacy in those who needed it.
Timeline
2014 to 2020: Patients in the registry were treated with CT-guided cryoablation.
November 19-21, 2026: Results were presented at IKCS: North America 2026 in Dallas, Texas.
Health Landscape
The EuRECA registry is building a multicenter evidence base for renal cryoablation as an alternative to surgery for small kidney tumors. These five-year outcomes extend that dataset for clinicians managing patients who are less suitable for surgery.
For patients with small kidney tumors who are poor candidates for surgery, these results indicate that a percutaneous ablation option has documented five-year control rates. Treatment decisions remain individualized and should be made with a treating physician.
The takeaway
Long-term registry data can clarify how well minimally invasive kidney cancer treatments hold up over time. Patients weighing options should discuss recurrence and survival figures with their care team.
Further reading
Explore more on Cancer research and treatment developments.
Source note: This article includes information reported by Cancer Therapy Advisor.



